Showing results (21-30 of 492) with videos related to

Sort By:
Pageof 50
The Lancet. Diabetes & Endocrinology|August 14, 2025
The central role of recovery of β-cell function in the remission of prediabetes: a prospective cohort study in CanadaRavi Retnakaran, Jiajie Pu, Junwei Shen, et al.
Diabetes Research and Clinical Practice|May 21, 2014
Emerging parameters of the insulin and glucose response on the oral glucose tolerance test: reproducibility and implications for glucose homeostasis in individuals with and without diabetesCaroline Kaercher Kramer, Vladimir Vuksan, Haysook Choi, et al.
Diabetes, Obesity & Metabolism|June 28, 2023
Baseline determinants of remission of type 2 diabetes in response to short-term insulin-based therapy: The pivotal role of beta-cell functionRavi Retnakaran, Jiajie Pu, Alexandra Emery, et al.
Diabetes Care|September 25, 2014
Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: the LIBRA trialRavi Retnakaran, Caroline K Kramer, Haysook Choi, et al.
American Journal of Physiology. Endocrinology and Metabolism|November 30, 2017
Effect of chronic liraglutide therapy and its withdrawal on time to postchallenge peak glucose in type 2 diabetesSusan Tran, Caroline K Kramer, Bernard Zinman, et al.
Diabetes, Obesity & Metabolism|January 30, 2018
Two-year trial of intermittent insulin therapy vs metformin for the preservation of β-cell function after initial short-term intensive insulin induction in early type 2 diabetesRavi Retnakaran, Haysook Choi, Chang Ye, et al.
Nature Communications|October 16, 2022
The metabolic effects of adding exenatide to basal insulin therapy when targeting remission in early type 2 diabetes in a randomized clinical trialRavi Retnakaran, Chang Ye, Alexandra Emery, et al.
Diabetes Care|June 29, 2011
Changes over time in glycemic control, insulin sensitivity, and beta-cell function in response to low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose toleranceRavi Retnakaran, Ying Qi, Stewart B Harris, et al.
The Journal of Clinical Endocrinology and Metabolism|August 1, 2015
The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA TrialCaroline K Kramer, Bernard Zinman, Haysook Choi, et al.
Diabetes, Obesity & Metabolism|February 10, 2017
Chronic liraglutide therapy induces an enhanced endogenous glucagon-like peptide-1 secretory response in early type 2 diabetesCaroline K Kramer, Bernard Zinman, Haysook Choi, et al.
Pageof 50